ECSP045167A - NUCLEÓSIDOS 3-ß-D-RIBOFURANOSILTIAZOL[4,5-d]PIRIDIMINA Y SUS USOS - Google Patents

NUCLEÓSIDOS 3-ß-D-RIBOFURANOSILTIAZOL[4,5-d]PIRIDIMINA Y SUS USOS

Info

Publication number
ECSP045167A
ECSP045167A EC2004005167A ECSP045167A ECSP045167A EC SP045167 A ECSP045167 A EC SP045167A EC 2004005167 A EC2004005167 A EC 2004005167A EC SP045167 A ECSP045167 A EC SP045167A EC SP045167 A ECSP045167 A EC SP045167A
Authority
EC
Ecuador
Prior art keywords
threaded
ribofuranosiltiazol
nucleosids
pyridimine
male
Prior art date
Application number
EC2004005167A
Other languages
English (en)
Inventor
Devron R Averett
Stephen E Webber
Joseph R Lennox
Erik J Rueden
Original Assignee
Anadys Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anadys Pharmaceuticals Inc filed Critical Anadys Pharmaceuticals Inc
Publication of ECSP045167A publication Critical patent/ECSP045167A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/22—Pteridine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Joints Allowing Movement (AREA)

Abstract

Se describe una junta roscada integral del tipo nivelado con roscados de cono truncado, con dos superficies de sellado 11', 12', 11'', 12'' ajustadas en el extremo de las porciones roscadas (7, 8) y con dos resaltos de sellado anulares (5', 6', 5'', 6''). Las dos porciones roscadas (7, 8) del elemento macho (1) y el elemento hembra (2) respectivamente, tienen el mismo valor de conicidad y las dos superficies de sellado (11', 12', 11'', 12'') son en un caso cónicas o cilíndricas y en el otro esféricas. La porción roscada de cada elemento macho y hembra puede tener un área del extremo con un roscado que no es perfecto.
EC2004005167A 2001-11-27 2004-06-22 NUCLEÓSIDOS 3-ß-D-RIBOFURANOSILTIAZOL[4,5-d]PIRIDIMINA Y SUS USOS ECSP045167A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33346001P 2001-11-27 2001-11-27

Publications (1)

Publication Number Publication Date
ECSP045167A true ECSP045167A (es) 2004-10-26

Family

ID=23302891

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005167A ECSP045167A (es) 2001-11-27 2004-06-22 NUCLEÓSIDOS 3-ß-D-RIBOFURANOSILTIAZOL[4,5-d]PIRIDIMINA Y SUS USOS

Country Status (28)

Country Link
US (3) US6924271B2 (es)
EP (1) EP1451203B1 (es)
JP (1) JP4493337B2 (es)
KR (1) KR100718371B1 (es)
CN (2) CN1300165C (es)
AP (1) AP2004003069A0 (es)
AT (1) ATE448238T1 (es)
AU (1) AU2002365412B2 (es)
BR (1) BR0214407A (es)
CA (1) CA2468552C (es)
CO (1) CO5590931A2 (es)
DE (1) DE60234376D1 (es)
EA (1) EA008380B1 (es)
EC (1) ECSP045167A (es)
ES (1) ES2333945T3 (es)
GE (1) GEP20074099B (es)
HR (1) HRP20040541A2 (es)
IL (1) IL162137A0 (es)
IS (1) IS7283A (es)
MA (1) MA27156A1 (es)
MX (1) MXPA04004966A (es)
NO (1) NO20042676L (es)
NZ (1) NZ533628A (es)
OA (1) OA12729A (es)
TN (1) TNSN04113A1 (es)
UA (1) UA79764C2 (es)
WO (1) WO2003045968A1 (es)
YU (1) YU45204A (es)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1850850A4 (en) * 2000-12-08 2011-06-15 3M Innovative Properties Co COMPOSITIONS AND METHOD FOR TARGETED ADMINISTRATION OF IMMUNE RESPONSE MODIFICATORS
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
HUE025145T2 (en) * 2002-02-22 2016-01-28 Meda Ab A method for reducing and treating immunosuppression induced by ultraviolet B radiation
EP2572714A1 (en) * 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
JP2006517974A (ja) * 2003-02-13 2006-08-03 スリーエム イノベイティブ プロパティズ カンパニー Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物
EP1599726A4 (en) * 2003-02-27 2009-07-22 3M Innovative Properties Co SELECTIVE MODULATION OF TLR-MEDIATED BIOLOGICAL ACTIVITY
JP2006519866A (ja) 2003-03-04 2006-08-31 スリーエム イノベイティブ プロパティズ カンパニー Ｕｖ誘発性の表皮の新形成の予防的治療
AU2004220465A1 (en) 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
KR20050109562A (ko) * 2003-03-13 2005-11-21 쓰리엠 이노베이티브 프로퍼티즈 컴파니 피부의 질을 개선시키는 방법
US20040192585A1 (en) * 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
EP1615665A4 (en) 2003-04-10 2010-10-06 3M Innovative Properties Co DISTRIBUTION OF THE IMMUNE RESPONSE MODIFYING LINKS
US20080039533A1 (en) * 2003-07-31 2008-02-14 3M Innovative Properties Company Bioactive Compositions Comprising Triazines
BRPI0413558A (pt) 2003-08-12 2006-10-17 3M Innovative Properties Co compostos contendo imidazo substituìdo por hidroxilamina
JP2007504145A (ja) * 2003-08-25 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー 免疫刺激性の組み合わせおよび治療
AU2004268625B2 (en) 2003-08-27 2011-03-31 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
JP2007504232A (ja) 2003-09-05 2007-03-01 アナディス ファーマシューティカルズ インク Ｃ型肝炎ウイルス感染治療用のｔｌｒ７リガンド及びそのプロドラッグの投与
AU2004270201A1 (en) 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for CD5+ B cell lymphoma
EP1664342A4 (en) * 2003-09-17 2007-12-26 3M Innovative Properties Co SELECTIVE MODULATION OF TLR GENE EXPRESSION
AR046046A1 (es) 2003-10-03 2005-11-23 3M Innovative Properties Co Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas.
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
JP2007509987A (ja) * 2003-10-31 2007-04-19 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調節剤化合物による好中球活性化
EP1685129A4 (en) 2003-11-14 2008-10-22 3M Innovative Properties Co OXIMSUBSTITUTED IMIDAZORING CONNECTIONS
CA2545825A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
CA2547020C (en) 2003-11-25 2014-03-25 3M Innovative Properties Company 1h-imidazo[4,5-c]pyridine-4-amine derivatives as immune response modifier
US20050226878A1 (en) * 2003-12-02 2005-10-13 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
US8940755B2 (en) * 2003-12-02 2015-01-27 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
JP2007517035A (ja) 2003-12-29 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー アリールアルケニルおよびアリールアルキニル置換されたイミダゾキノリン
EP1699788A2 (en) 2003-12-30 2006-09-13 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl and imidazonaphthyridinyl sulfonamides
US20050239735A1 (en) * 2003-12-30 2005-10-27 3M Innovative Properties Company Enhancement of immune responses
WO2005094531A2 (en) 2004-03-24 2005-10-13 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
JP2007532572A (ja) * 2004-04-09 2007-11-15 スリーエム イノベイティブ プロパティズ カンパニー 免疫反応調整剤を送達させるための方法、組成物および調製物
MXPA06012451A (es) * 2004-04-28 2007-01-31 3M Innovative Properties Co Composiciones y metodos para vacunacion por la mucosa.
US20050267145A1 (en) * 2004-05-28 2005-12-01 Merrill Bryon A Treatment for lung cancer
US20080154210A1 (en) 2004-05-28 2008-06-26 Oryxe Mixture for Transdermal Delivery of Low and High Molecular Weight Compounds
CA2566541C (en) * 2004-06-07 2012-10-09 Anadys Pharmaceuticals, Inc. 3-.beta.-d-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and uses thereof
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
WO2006026470A2 (en) * 2004-08-27 2006-03-09 3M Innovative Properties Company Hiv immunostimulatory compositions
EP1804583A4 (en) * 2004-10-08 2009-05-20 3M Innovative Properties Co ADJUVANT FOR DNA VACCINE
US7560544B2 (en) 2004-12-17 2009-07-14 Anadys Pharmaceuticals, Inc. 3,5-Disubsitituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof
JP5543068B2 (ja) 2004-12-30 2014-07-09 スリーエム イノベイティブ プロパティズ カンパニー キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
EP1831221B1 (en) 2004-12-30 2012-08-08 3M Innovative Properties Company Substituted chiral fused 1,2 imidazo 4,5-c ring compounds
PL1830876T3 (pl) 2004-12-30 2015-09-30 Meda Ab Zastosowanie imikwimodu do leczenia przerzutów do skóry wywodzących się od guza stanowiącego raka piersi
AU2006210392A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune response modifiers
AU2006213746A1 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo(4,5-c) ring compounds and methods
SI1858920T1 (sl) 2005-02-18 2016-07-29 Glaxosmithkline Biologicals S.A. Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 尿路病原性菌株由来の抗原
ATE534652T1 (de) 2005-04-01 2011-12-15 Univ California Phosphono-pent-2-en-1-yl-nukleoside und analoga
EP1869043A2 (en) 2005-04-01 2007-12-26 Coley Pharmaceutical Group, Inc. Pyrazolopyridine-1,4-diamines and analogs thereof
AU2006232375A1 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
EP1909564A4 (en) 2005-07-18 2010-06-30 Novartis Ag SMALL ANIMAL MODEL FOR HCV REPLICATION
JP5517454B2 (ja) * 2005-09-30 2014-06-11 スシネキス インク Ｃ型肝炎感染の治療及び予防のための方法及び医薬組成物
EP1931696B1 (en) 2005-09-30 2011-02-16 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine a for the treatment and prevention of viral infection
CN102755645A (zh) 2005-11-04 2012-10-31 诺华疫苗和诊断有限公司 佐剂配制的包含细胞因子诱导剂的流感疫苗
NZ594482A (en) 2005-11-04 2012-11-30 Novartis Vaccines & Diagnostic Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
NZ568211A (en) 2005-11-04 2011-11-25 Novartis Vaccines & Diagnostic Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
CA2628152C (en) 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
DE602006015700D1 (de) 2005-11-21 2010-09-02 Anadys Pharmaceuticals Inc Neues verfahren zur herstellung von 5-amino-3h-thiazoloä4,5-düpyrimidin-2-on
PL2478916T3 (pl) 2006-01-27 2020-11-16 Seqirus UK Limited Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy
EP1988896A4 (en) 2006-02-22 2011-07-27 3M Innovative Properties Co CONJUGATES TO MODIFY IMMUNE REACTIONS
EP2010530A2 (en) * 2006-03-23 2009-01-07 Novartis AG Methods for the preparation of imidazole-containing compounds
ES2536426T3 (es) * 2006-03-23 2015-05-25 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores
US8063063B2 (en) * 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
CN101448523A (zh) 2006-03-24 2009-06-03 诺华疫苗和诊断有限两合公司 无需冷藏储存流感疫苗
EP2382988A1 (en) 2006-03-31 2011-11-02 Novartis AG Combined mucosal and parenteral immunization against HIV
EP2007789B1 (en) 2006-04-11 2015-05-20 Novartis AG Spirocyclic HCV/HIV inhibitors and their uses
CL2007001427A1 (es) * 2006-05-22 2008-05-16 Novartis Ag Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po
PT2054431E (pt) 2006-06-09 2011-11-03 Novartis Ag Confórmeros de adesinas bacterianas
KR101461604B1 (ko) * 2006-06-22 2014-11-18 애나디스 파마슈티칼스, 인코포레이티드 5-아미노-3-(3''-데옥시-β-Ｄ-리보퓨라노실)-티아졸로［4,5-ｄ］파이리미딘-2,7-다이온의 프로드럭
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
WO2008011406A2 (en) * 2006-07-18 2008-01-24 Anadys Pharmaceuticals, Inc. Carbonate and carbamate prodrugs of thiazolo [4,5-d] pyrimidines
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
EP4585610A3 (en) 2006-09-11 2025-09-24 Seqirus UK Limited Making influenza virus vaccines without using eggs
BRPI0717741A2 (pt) * 2006-10-17 2014-04-08 Anadys Pharmaceuticals Inc Compostos e respectivos método de preparação, método de redução de composto de sulfonil substituído, composição farmacêutica método de tratamento ou prevenção de doença
WO2008069917A2 (en) 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
KR100880298B1 (ko) * 2006-12-06 2009-01-28 애나디스 파마슈티칼스, 인코포레이티드 ３-β-Ｄ-리보푸라노실티아졸로[４,５-ｄ]피리미딘뉴클레오시드 및 이의 용도
PT2121011E (pt) 2006-12-06 2014-07-31 Novartis Ag Vacinas compreendendo um antigénio a partir de quatro estirpes do vírus da gripe
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
WO2008127613A1 (en) * 2007-04-11 2008-10-23 Scynexis, Inc. New pharmaceutical compositions
KR20100045437A (ko) 2007-06-27 2010-05-03 노파르티스 아게 첨가물이 적은 인플루엔자 백신
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
WO2009026292A1 (en) * 2007-08-20 2009-02-26 Anadys Pharmaceuticals, Inc. Dosing methods for treating disease
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
JP5518041B2 (ja) 2008-03-18 2014-06-11 ノバルティス アーゲー インフルエンザウイルスワクチン抗原の調製における改良
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
CN102083852A (zh) * 2008-06-06 2011-06-01 西尼克斯公司 环孢菌素类似物及其在治疗hcv感染中的应用
EP2376524B1 (en) 2008-12-31 2017-03-15 Cypralis Limited Derivatives of cyclosporin a
US8568732B2 (en) 2009-03-06 2013-10-29 Novartis Ag Chlamydia antigens
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
EP3263128A3 (en) 2009-04-14 2018-01-24 GlaxoSmithKline Biologicals S.A. Compositions for immunising against staphylococcus aureus
USH2283H1 (en) 2009-04-27 2013-09-03 Novartis Ag Vaccines for protecting against influenza
US10988511B2 (en) 2009-07-07 2021-04-27 Glaxosmithkline Biologicals Sa Conserved Escherichia bacterial IG-like domain (group 1) protein (ORF405) immunogens
CA2768186A1 (en) 2009-07-15 2011-01-20 Novartis Ag Rsv f protein compositions and methods for making same
AU2010272243A1 (en) 2009-07-16 2012-03-08 Novartis Ag Detoxified Escherichia coli immunogens
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
US20110144005A1 (en) 2009-12-09 2011-06-16 Scynexis, Inc. Novel cyclic peptides
WO2011080595A2 (en) 2009-12-30 2011-07-07 Novartis Ag Polysaccharide immunogens conjugated to e. coli carrier proteins
KR20130121699A (ko) 2010-05-28 2013-11-06 테트리스 온라인, 인코포레이티드 상호작용 혼성 비동기 컴퓨터 게임 기반구조
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
JP5909495B2 (ja) 2010-10-08 2016-04-26 ノバルティス アーゲー スルファミドｎｓ３阻害剤のビタミンｅ製剤
WO2012103361A1 (en) 2011-01-26 2012-08-02 Novartis Ag Rsv immunization regimen
CN102153548B (zh) * 2011-02-24 2012-11-28 河北大学 一种含有噻唑（嗪）烷酮环的类核苷衍生物及其制备方法和其在药物制剂中的应用
CA2835644C (en) 2011-05-13 2021-06-15 Novartis Ag Pre-fusion rsv f antigens
BR112013031039B1 (pt) 2011-06-03 2020-04-28 3M Innovative Properties Co compostos de hidrazino 1h-imidazoquinolina-4-aminas, conjugados feitos destes compostos, composição e composição farmacêutica compreendendo ditos compostos e conjugados, usos dos mesmos e método de fabricação do conjugado
JP6460789B2 (ja) 2011-06-03 2019-01-30 スリーエム イノベイティブ プロパティズ カンパニー ポリエチレングリコールセグメントを有するヘテロ２官能性リンカー及び該リンカーから調製された免疫反応調節複合体
EP2729178A1 (en) 2011-07-08 2014-05-14 Novartis AG Tyrosine ligation process
RU2636350C2 (ru) 2011-11-07 2017-11-22 Новартис Аг МОЛЕКУЛА, СОДЕРЖАЩАЯ SPR0096 и SPR2021
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
TR201808684T4 (tr) 2012-10-02 2018-07-23 Glaxosmithkline Biologicals Sa Lineer olmayan sakarit konjügatları.
CN111249455A (zh) 2012-11-30 2020-06-09 葛兰素史密丝克莱恩生物有限公司 假单胞菌抗原和抗原组合
WO2014107663A2 (en) 2013-01-07 2014-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cutaneous t cell lymphoma
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
DK3092256T3 (da) 2014-01-10 2022-06-20 Birdie Biopharmaceuticals Inc Forbindelser og sammensætninger til immunterapi
CN121243402A (zh) 2014-07-09 2026-01-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1组合
CN105233291A (zh) 2014-07-09 2016-01-13 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
US11260018B2 (en) 2015-09-17 2022-03-01 Jrx Biotechnology, Inc. Approaches for improving skin hydration and moisturization
WO2017059280A1 (en) 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-egfr组合
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
CA3067268A1 (en) 2017-06-23 2018-12-27 Birdie Biopharmaceuticals, Inc. Crystalline resiquimod monosulfate anhydrate and its preparation and uses
AU2019228381B2 (en) 2018-02-28 2021-12-16 Pfizer Inc. IL-15 variants and uses thereof
MX2020012607A (es) 2018-05-23 2021-01-29 Pfizer Anticuerpos especificos para gucy2c y sus usos.
KR102602329B1 (ko) 2018-05-23 2023-11-16 화이자 인코포레이티드 Cd3에 특이적인 항체 및 이의 용도
US20220370606A1 (en) 2018-12-21 2022-11-24 Pfizer Inc. Combination Treatments Of Cancer Comprising A TLR Agonist
CA3164623A1 (en) 2019-12-17 2021-06-24 Pfizer Inc. Antibodies specific for cd47, pd-l1, and uses thereof
MX2023000662A (es) 2020-07-17 2023-02-27 Pfizer Anticuerpos terapeuticos y sus usos.
TW202317144A (zh) 2021-06-14 2023-05-01 美商維納拓爾斯製藥公司 口服生物可利用的核苷類似物
WO2023196458A1 (en) * 2022-04-06 2023-10-12 VenatoRx Pharmaceuticals, Inc. Orally-bioavailable nucleoside analogs
WO2025104289A1 (en) 2023-11-17 2025-05-22 Medincell S.A. Antineoplastic combinations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4746651A (en) 1983-11-01 1988-05-24 Scripps Clinic And Research Foundation Antimicrobial chemotherapeutic potentiation using substituted nucleoside derivatives
GB8712745D0 (en) 1987-05-30 1987-07-01 Wellcome Found Antiviral compounds
US5041426A (en) * 1987-12-21 1991-08-20 Brigham Young University Immune system enhancing 3-β-d-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and nucleotides
US4880784A (en) 1987-12-21 1989-11-14 Brigham Young University Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives
GB9015914D0 (en) 1990-07-19 1990-09-05 Wellcome Found Heterocyclic compounds
US5248672A (en) 1990-11-01 1993-09-28 The Regents Of The University Of Michigan Polysubstituted benzimidazole nucleosides as antiviral agents
GB9105899D0 (en) 1991-03-20 1991-05-08 Wellcome Found Therapeutic nucleosides
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
BR9714349A (pt) 1996-10-16 2000-11-14 Icn Pharmaceuticals L-nucleosìdeos purina, seus análogos e utilizacões dos mesmos
US6509320B1 (en) 1996-10-16 2003-01-21 Icn Pharmaceuticals, Inc. Purine L-nucleosides, analogs and uses thereof
US6444652B1 (en) * 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B

Also Published As

Publication number Publication date
US6924271B2 (en) 2005-08-02
KR20040065230A (ko) 2004-07-21
EA008380B1 (ru) 2007-04-27
JP4493337B2 (ja) 2010-06-30
WO2003045968A1 (en) 2003-06-05
ATE448238T1 (de) 2009-11-15
DE60234376D1 (de) 2009-12-24
US20030199461A1 (en) 2003-10-23
CA2468552A1 (en) 2003-06-05
IL162137A0 (en) 2005-11-20
EA200400735A1 (ru) 2004-12-30
ES2333945T3 (es) 2010-03-03
MA27156A1 (fr) 2005-01-03
EP1451203B1 (en) 2009-11-11
JP2005515196A (ja) 2005-05-26
US20080090844A1 (en) 2008-04-17
AU2002365412B2 (en) 2008-10-09
NZ533628A (en) 2006-07-28
CA2468552C (en) 2011-09-20
HRP20040541A2 (en) 2004-10-31
IS7283A (is) 2004-05-21
MXPA04004966A (es) 2006-03-21
YU45204A (sh) 2006-08-17
NO20042676L (no) 2004-08-24
OA12729A (en) 2006-06-28
CO5590931A2 (es) 2005-12-30
CN1612889A (zh) 2005-05-04
AP2004003069A0 (en) 2004-06-30
BR0214407A (pt) 2004-10-19
TNSN04113A1 (en) 2006-06-01
AU2002365412A1 (en) 2003-06-10
CN1300165C (zh) 2007-02-14
EP1451203A1 (en) 2004-09-01
US20050182001A1 (en) 2005-08-18
UA79764C2 (en) 2007-07-25
KR100718371B1 (ko) 2007-05-14
CN101033242A (zh) 2007-09-12
GEP20074099B (en) 2007-05-10

Similar Documents

Publication Publication Date Title
ECSP045167A (es) NUCLEÓSIDOS 3-ß-D-RIBOFURANOSILTIAZOL[4,5-d]PIRIDIMINA Y SUS USOS
ECSP034465A (es) Junta roscada integral de perfil continuo para tubos
ES2176390T3 (es) Endoprotesis para una articulacion artificial de cadera.
DE3860282D1 (de) Selbstschneidendes einschraubbares knochenimplantat fuer zahnaerztliche zwecke.
US4626214A (en) Fixed dental implant
DE69941016D1 (de) Medizinische Vorrichtung mit einem Gewinde mit rückwärts gerichteten tragenden Flächen
CA2292318A1 (en) Pipe joint
JPH04503023A (ja) 複数の部材より成る義歯をねじ結合するためのねじ体
BR0112323A (pt) União rosqueada integral de tubos
WO2003032331A3 (en) Radially expandable tubular connection
CA2383809A1 (en) Suture anchor
KR920702766A (ko) 파이프 커플링
DE69333281D1 (de) Befestigungsvorrichtung für eine Hüftgelenkprothese
ATE249176T1 (de) Knochenschraube
ES2070236T3 (es) Dispositivo de tornillo para fijar protesis a los huesos.
DE59307208D1 (de) Verankerungselement
SE0203896D0 (sv) Anordning vid implantat
CA2389216A1 (en) Tube connection
ES2187706T3 (es) Tornillo con una punta de autoperforante.
ES2391554T3 (es) Acoplamiento cónico y prótesis que comprende dicho acoplamiento
ES2034775T3 (es) Remache ciego autotaladrante y su procedimiento de fabricacion.
EP1112722A3 (de) Implantat-Element mit selbstschneidendem Gewinde
DE59805861D1 (de) Verbindungsmuffe und Vorrichtung zur Befestigung von Gegenständen an Wänden oder dgl.
HUT68722A (en) Member provided with an external screw thread
ES2154070T3 (es) Casquillo con rosca